ClinicalTrials.gg
CompletedNCT07349628BRIDGE-HERNIAUpdated Jan 20, 2026

Botulinum Toxin A Facilitates Fascial Closure in Complex Incisional Hernias

An observational study in Incisional Hernia, sponsored by Azienda Sanitaria Locale Napoli 2 Nord. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Azienda Sanitaria Locale Napoli 2 Nord · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
32
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Incisional Hernia with a site in Italy — 4 open to participants now, 5 under way, none of them phase 3. Incisional Hernia · Italy.

Started
2021
with 2 others
Observational
8 of 16
2 open now
Registered
14th of 16
by date
Lead sponsor
5 of 16
Azienda Sanitaria Locale Napoli 2 Nord

Among the 16 studies in Incisional Hernia with a site in Italy, this one is one of 3 that started in 2021, is one of 8 observational ones, and was the 14th registered.

Incisional Hernia

212 studies on the registry are indexed under Incisional Hernia; 58 are open to participants now.

Browse Incisional Hernia studies →

Open to participants now

4 of the 16 studies in Incisional Hernia with a site in Italy are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 39 Incisional Hernia studies recruiting now, 28 (72%) set no upper age limit and 2 (5%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Incisional Hernia with a site in Italy, or all of them as a file.
02

Study summary

Brief Study Description

This prospective observational study evaluates the use of preoperative botulinum toxin A as part of a structured clinical pathway for patients undergoing elective repair of complex midline incisional hernias. Botulinum toxin A is administered before surgery to temporarily relax the abdominal wall muscles, with the aim of improving abdominal wall flexibility and facilitating closure of the hernia without the need for more extensive surgical techniques. The study collects clinical, radiological, and postoperative outcome data to assess surgical feasibility, complications, and early recurrence. The overall goal is to better understand how preoperative muscle relaxation may support safer and more effective abdominal wall reconstruction.

Read the detailed description

Detailed Description

This prospective observational study investigates a preoperative strategy designed to improve surgical outcomes in patients with complex midline incisional hernias. These hernias often involve large abdominal wall defects and significant muscle retraction, which can make surgical repair difficult and increase the risk of complications. To address these challenges, the study evaluates the use of botulinum toxin A administered before surgery as part of a standardized clinical pathway known as the BRIDGE-HERNIA protocol.

Botulinum toxin A is injected into the lateral abdominal wall muscles several weeks before the planned operation. Its temporary muscle-relaxing effect increases the flexibility of the abdominal wall, which may allow surgeons to close the hernia defect more easily and avoid more invasive surgical techniques. All patients undergo detailed preoperative assessment, including imaging studies, to evaluate abdominal wall anatomy and to plan the surgical approach. After botulinum toxin administration, imaging is repeated to assess changes in muscle length and hernia dimensions.

The study prospectively collects clinical, radiological, surgical, and postoperative data. Primary outcomes include the feasibility of achieving direct fascial closure without advanced component separation techniques. Secondary outcomes include postoperative complications, length of hospital stay, early hernia recurrence, and patient-reported quality of life. Because the study is observational, all treatments are delivered according to routine clinical practice, and no additional experimental interventions are assigned by the study protocol.

The results of this study aim to improve understanding of how preoperative muscle relaxation can support safer and less invasive surgical repair of complex incisional hernias, and to provide evidence that may help optimize surgical planning and patient selection in abdominal wall reconstruction.

03

Conditions studied

  • Incisional Hernia

Browse trials for

Keywords

  • Complex incisional hernia
  • Ventral hernia repair
  • Abdominal wall reconstruction
  • Botulinum toxin injection
  • Prehabilitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  • Emergency hernia repair
  • Lateral or non-midline incisional hernia
  • Presence of true loss of domain requiring alternative surgical strategies
  • Previous allergic reaction or contraindication to botulinum toxin A
  • Neuromuscular disorders contraindicating botulinum toxin administration
  • Pregnancy or breastfeeding
  • Inability to comply with planned follow-up schedule

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of complex midline incisional hernia
  • Planned elective surgical repair of the incisional hernia
  • Preoperative management including botulinum toxin A administration as part of routine clinical care
  • Ability to undergo contrast-enhanced computed tomography imaging
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
32 participants (actual)
Target follow-up
32 Years
Patient registry
Yes

Groups and cohorts

  • Patients with complex midline incisional hernia

    his cohort includes adult patients with complex midline incisional hernias undergoing elective surgical repair within a standardized clinical pathway that incorporates preoperative botulinum toxin A administration. Participants are prospectively followed to collect clinical, radiological, surgical, and postoperative outcome data as part of routine clinical care.

06

What researchers measure

Primary outcomes

  1. Rate of fascial closure without transversus abdominis release

    The proportion of patients in whom midline fascial closure is achieved using the Rives-Stoppa technique without the need for transversus abdominis release during elective repair of complex midline incisional hernias following preoperative botulinum toxin A administration.

    Time frame: During surgery (index procedure)

Secondary outcomes

  1. Radiological changes in abdominal wall morphology

    Changes in transverse hernia defect width and lateral abdominal wall muscle elongation assessed by computed tomography before and after preoperative botulinum toxin A administration.

    Time frame: Baseline and 5 weeks after botulinum toxin A injection

  2. Postoperative complications

    Incidence of postoperative complications, including surgical site occurrences.

    Time frame: Up to 30 days after surgery

  3. Length of hospital stay

    Duration of postoperative hospital stay measured in days following elective hernia repair.

    Time frame: Immediately after surgery

  4. Early hernia recurrence

    Occurrence of clinically or radiologically confirmed hernia recurrence during postoperative follow-up.

    Time frame: Up to 12 months after surgery

07

Study locations

1 site
  • Aslnapoli2Nord
    Naples, Naples 80131, Italy
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. This study is a single-center prospective observational cohort with a limited sample size, and the collected clinical and imaging data may contain potentially identifiable information. No formal data-sharing plan was included in the original study protocol, and no approval for external data sharing was obtained from the local ethics committee. Aggregate data are reported in publications, and additional information may be considered upon reasonable request and subject to institutional and ethical approval.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jan 2025, 48 months.

Of 24 observational studies under Incisional Hernia, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 61. This study's 48 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 20, 2026
StartActual
Jan 1, 2021
Primary completionActual
Jan 1, 2025
CompletionActual
Mar 31, 2025
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07349628
Lead sponsor
Azienda Sanitaria Locale Napoli 2 Nord
Responsible party
Francesco Pizza (Principal Investigator,, Azienda Sanitaria Locale Napoli 2 Nord) — Principal investigator
First posted
Jan 20, 2026
Start date
Jan 1, 2021
Primary completion
Jan 1, 2025
Completion
Mar 31, 2025
Last update
Jan 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion